Brevan Howard Capital Management
BEAM icon

Brevan Howard Capital Management’s Beam Therapeutics BEAM Stock Holding History

Brevan Howard Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$990K Buy
+28,859
New +$871K 0.01% 1060
2025
Q4 		– Sell
-49,811
Closed -$1.18M – 1811
2025
Q3 		$1.18M Buy
+49,811
New +$991K 0.01% 823
2021
Q2 		– Sell
-30,000
Closed -$2.4M – 42
2021
Q1 		$2.4M Buy
+30,000
New +$2.85M 0.35% 39

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Brevan Howard Capital Management's BEAM Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 28,859 shares worth $990K. The stake represents 0.01% of the portfolio and ranks #1060 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in BEAM as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in BEAM in Q1 2021 and has held it in 3 quarters since. The position peaked at $2.4M in Q1 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Brevan Howard Capital Management held 28,859 shares of Beam Therapeutics worth $990K as of Q2 2026.
  • Beam Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
  • Beam Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1060 holding.
  • Brevan Howard Capital Management first reported a position in Beam Therapeutics in Q1 2021 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Beam Therapeutics position peaked at $2.4M in Q1 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.